The experts speak. Studying the potential of tenofovir to prevent sexual transmission of HIV: first steps. Interview by Vicki Glaser.
Melanie Thompson, M.D., is Founder and Principal Investigator of the AIDS Research Consortium of Atlanta (ARCA), one of the first non-profit community-based HIV/AIDS research centers in the United States and the primary resource for HIV clinical research in Georgia. Dr. Thompson is also a private practitioner in Atlanta and serves on the International AIDS Society- USA's Antiretroviral Guidelines Panel. She is the past chair of the National Institutes of Health Office of AIDS Research Therapeutics Research Working Group. Dr. Thompson has served as ARCA's principal investigator for more than 200 studies involving more than 12,000 patients. To date, ARCA's studies have contributed to the FDA approval of 21 treatments for HIV and its complications.
Thompson
Melanie
M
AIDS Research Consortium of Atlanta, Atlanta, Georgia, USA.
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D003140:Communicable Disease Control; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D011322:Primary Prevention / Q000379:methods; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012749:Sexually Transmitted Diseases / Q000517:prevention & control*; D000068698:Tenofovir; D016896:Treatment Outcome
D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine